Intellia Therapeutics
NTLA
302 hedge funds and large institutions have $2.69B invested in Intellia Therapeutics in 2022 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 119 increasing their positions, 81 reducing their positions, and 60 closing their positions.
95% more call options, than puts
Call options by funds: $22.8M | Put options by funds: $11.7M
47% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 81
0.93% more ownership
Funds ownership: 89.52% → 90.45% (+0.93%)
6% less funds holding
Funds holding: 321 → 302 (-19)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
22% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 60
29% less capital invested
Capital invested by funds: $3.81B → $2.69B (-$1.12B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$67.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.7M |
| 3 |
BlackRock
New York
|
+$53.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$50.7M |
| 5 |
Morgan Stanley
New York
|
+$47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$19.3M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$17.2M |
| 3 |
Goldman Sachs
New York
|
-$16.9M |
| 4 |
Millennium Management
New York
|
-$13.3M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$11.2M |
NTLA Hedge Fund Activity: Q4 2022 in Review
302 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2022, worth a combined $2.69B — down 29% from $3.81B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of NTLA and 47 opened new positions — a net loss of 13 holders — while 81 trimmed existing stakes and 119 added.
The largest buyer was Wellington Management Group, adding an estimated $67.5M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $19.3M sold.
- 302 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2022, down from 321 in Q3 2022.
- Funds reported $2.69B of Intellia Therapeutics stock for Q4 2022, down 29% quarter-over-quarter.
- 47 funds opened new Intellia Therapeutics positions in Q4 2022 and 60 closed out, a net change of -13 holders.
- The largest Intellia Therapeutics buyer in Q4 2022 was Wellington Management Group, an estimated $67.5M added.
- The largest Intellia Therapeutics seller in Q4 2022 was PFM Health Sciences, an estimated $19.3M sold.
Based on aggregated 13F filings for Q4 2022.